Antibody Drug Discovery Services

Antibody drug discovery is an analytical approach based on advanced biotechnology platforms dedicated to developing highly specific, high-affinity, and highly potent therapeutic antibodies. The core principle involves screening, optimizing, and characterizing antibody molecules to identify those that specifically target disease-related proteins or antigens, thereby serving as therapeutic agents. By leveraging the natural properties of antibodies and their engineering potential, these antibody drugs can effectively block pathological signaling pathways or directly kill target cells, demonstrating significant therapeutic potential.

Antibody drug discovery services are widely used in fields such as oncology, autoimmune diseases, infectious diseases, and neurodegenerative disorders. For instance, in cancer treatment, antibody drugs can target tumor antigens, activating the immune system to eliminate cancer cells; in autoimmune diseases, they can alleviate symptoms by blocking abnormal immune signals; in infectious diseases, they can neutralize viral infections, providing immediate immune protection. This service has become a critical technological pillar for the development of next-generation biotherapeutics.

Lu, M R. et al. Journal of Biomedical Science, 2020.

Figure 1. Schematic overview showing the development of antibody-based therapeutics for the treatment of cancer.

Services at MtoZ Biolabs

Leveraging advanced high-throughput screening platforms, high-performance liquid chromatography (HPLC), and high-resolution mass spectrometry (LC-MS/MS), MtoZ Biolabs’s antibody drug discovery services offer comprehensive antibody screening, characterization, and optimization. By screening extensive antibody libraries, analyzing antigen binding capabilities and specificity, and validating functional effects, this service delivers high-affinity, high-specificity therapeutic antibody candidates along with robust experimental data.

Analysis Workflow

1. Target Selection and Validation

Identify disease-relevant molecular targets (e.g., specific antigens or receptors) and validate their biological function and disease association using genomics and proteomics technologies, ensuring the drug gability of the target.

2. Antibody Generation and Screening

Generate candidate antibodies using methods such as hybridoma technology, phage display libraries, and single B-cell sequencing. High-throughput screening is then performed to evaluate affinity, specificity, and cross-reactivity, ultimately selecting the most promising antibodies.

3. Antibody Optimization and Characterization

During the optimization phase, candidate antibodies undergo affinity maturation and humanization to enhance therapeutic efficacy. Advanced structural analysis and AI-driven design tools are utilized to improve binding efficiency, reduce immunogenicity, and enhance structural stability. Functional assays, including in vivo efficacy testing and biomarker validation, further confirm the potential of these candidate antibodies.

4. Candidate Antibody Screening

During the screening phase, candidate antibodies undergo comprehensive evaluation, including epitope mapping, glycan profiling, and binding kinetics analysis, to gain a thorough understanding of their performance. Additionally, risk assessments, safety analyses, and manufacturability studies are conducted to ensure compliance with clinical and regulatory standards. Ultimately, the most effective, safe, and scalable antibodies are selected, laying the groundwork for preclinical and clinical development.

5. Cell Line Development

The final stage of the antibody drug discovery services focuse on creating stable cell lines for large-scale production. Using advanced expression systems, stable cell lines are developed to ensure consistent and efficient antibody manufacturing.

Service Advantages

1. Advanced Analytical Platform

MtoZ Biolabs has established a cutting-edge antibody drug discovery services platform, ensuring reliable, rapid, and high-precision analytical services.

2. One-Time Charge

Our pricing is transparent, with no hidden or additional costs.

3. High-Throughput Screening

Leveraging advanced screening platforms and optimized strategies, we rapidly identify antibody candidates with high affinity and specificity from extensive antibody libraries.

4. Broad Applicability

Our services encompass a wide range of target types and disease areas, providing reliable support for drug development in oncology, immune disorders, infectious diseases, and more, facilitating efficient progression of antibody drug discovery projects.

5. Customized Solutions

We offer flexible, tailored antibody drug discovery strategies to meet the unique needs of pharmaceutical companies, biotechnology firms, and academic researchers.

Applications

1. Cancer Treatment

By screening antibodies specifically targeting tumor-associated antigens, the antibody drug discovery services facilitate the development of monoclonal antibodies, antibody-drug conjugates (ADCs), or bispecific antibodies. These antibodies activate the immune system to attack cancer cells or block oncogenic signaling pathways.

2. Autoimmune Diseases

Antibodies are employed to block inflammatory cytokines or immune regulatory pathways, thereby reducing inflammation and alleviating disease symptoms in patients.

3. Infectious Diseases

Develop neutralizing antibodies targeting viruses, bacteria, or other pathogens, providing rapid and effective immunotherapies for infection prevention and treatment.

4. Neurodegenerative Diseases

Screen and optimize antibodies capable of clearing abnormal proteins. The antibody drug discovery services can be applied to the treatment of neurodegenerative diseases, including Alzheimer's disease.

Case Study

1. Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants

This study aimed to discover a broadly neutralizing antibody capable of neutralizing multiple SARS-CoV-2 variants, including Omicron subvariants, and to evaluate the efficacy and feasibility of intranasal administration. The research subjects included patient samples and model systems. By screening antibodies from the blood samples of convalescent patients and combining structural biology with functional assays, a broadly neutralizing antibody targeting the receptor-binding domain of the coronavirus spike protein was identified and optimized. The results indicated that this antibody effectively neutralized multiple SARS-CoV-2 variants, including several Omicron subvariants, and demonstrated potent nasal protection in animal studies, reducing viral replication in the upper respiratory tract. The study concluded that the identified broadly neutralizing antibody not only exhibited excellent antiviral activity but also provided a rapid and convenient preventive approach via intranasal administration, thus offering an important immunological intervention strategy against the ongoing evolution of coronaviruses.